Phase 2/3RecruitingAge-related condition
Phase 2/3 Efficacy and Safety of PP405 in Adult Males (AWAKEN)
A Randomized, Multicenter, Double-blind, Vehicle-controlled, Phase 2/3 Study to Assess Efficacy and Long-Term Safety of PP405 in Adult Males With Androgenetic Alopecia
- Sponsor
- Pelage Pharmaceuticals, Inc. (Industry)
- Enrolment
- 600 planned
- Conditions
- Androgenetic Alopecia
- Interventions
- PP405 0.05% Topical Gel; Vehicle Topical Gel
- Ages
- adults
- Registry
- NCT07819435
Full record on ClinicalTrials.gov
From the registry
The study is designed to validate efficacy and long term safety of PP405.
Primary outcomes
- Change from baseline in non-vellus target area hair count
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered